OncoMatch/Triple-Negative Breast Cancer (TNBC)/BRCA2
Triple-Negative Breast Cancer (TNBC)BRCA2 Clinical Trials
Germline BRCA2 pathogenic variants occur in a subset of TNBC and are targetable with PARP inhibitors, which exploit the DNA repair defect created by BRCA2 loss. Olaparib and talazoparib are FDA-approved for germline BRCA1/2-positive HER2-negative metastatic breast cancer. Active trials study neoadjuvant PARP inhibitor strategies, somatic BRCA2 alteration eligibility, and platinum-based combinations in BRCA2-mutant TNBC.
Top recruiting BRCA2 Triple-Negative Breast Cancer (TNBC) trials
Ranked by phase and US site count. See all 3 trials matched to your profile →
Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Okayama University
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Emory University
Browse other molecular targets with active Triple-Negative Breast Cancer (TNBC) trials.